Source: unknown

<table>
  <tr>
    <th rowspan="2">(Millions of dollars)</th>
    <th colspan="3">2019</th>
    <th colspan="3">2018</th>
    <th colspan="3">2017</th>
  </tr>
  <tr>
    <th>United States</th>
    <th>International</th>
    <th>Total</th>
    <th>United States</th>
    <th>International</th>
    <th>Total</th>
    <th>United States</th>
    <th>International</th>
    <th>Total</th>
  </tr>
  <tr>
    <th colspan="10">Medical</th>
  </tr>
  <tr>
    <td>Medication Delivery Solutions</td>
    <td>$ 2,048</td>
    <td>$ 1,811</td>
    <td>$ 3,859</td>
    <td>$ 1,892</td>
    <td>$ 1,752</td>
    <td>$ 3,644</td>
    <td>$ 1,378</td>
    <td>$ 1,434</td>
    <td>$ 2,812</td>
  </tr>
  <tr>
    <td>Medication Management Solutions</td>
    <td>2,104</td>
    <td>525</td>
    <td>2,629</td>
    <td>1,957</td>
    <td>513</td>
    <td>2,470</td>
    <td>1,843</td>
    <td>452</td>
    <td>2,295</td>
  </tr>
  <tr>
    <td>Diabetes Care</td>
    <td>573</td>
    <td>538</td>
    <td>1,110</td>
    <td>564</td>
    <td>541</td>
    <td>1,105</td>
    <td>546</td>
    <td>510</td>
    <td>1,056</td>
  </tr>
  <tr>
    <td>Pharmaceutical Systems</td>
    <td>392</td>
    <td>1,073</td>
    <td>1,465</td>
    <td>357</td>
    <td>1,040</td>
    <td>1,397</td>
    <td>328</td>
    <td>929</td>
    <td>1,256</td>
  </tr>
  <tr>
    <td>Total segment revenues</td>
    <td>5,116</td>
    <td>3,947</td>
    <td>9,064</td>
    <td>4,770</td>
    <td>3,846</td>
    <td>8,616</td>
    <td>4,095</td>
    <td>3,325</td>
    <td>7,419</td>
  </tr>
  <tr>
    <th colspan="10">Life Sciences</th>
  </tr>
  <tr>
    <td>Preanalytical Systems</td>
    <td>774</td>
    <td>784</td>
    <td>1,558</td>
    <td>761</td>
    <td>792</td>
    <td>1,553</td>
    <td>741</td>
    <td>730</td>
    <td>1,471</td>
  </tr>
  <tr>
    <td>Diagnostic Systems</td>
    <td>672</td>
    <td>875</td>
    <td>1,547</td>
    <td>678</td>
    <td>858</td>
    <td>1,536</td>
    <td>622</td>
    <td>756</td>
    <td>1,378</td>
  </tr>
  <tr>
    <td>Biosciences</td>
    <td>485</td>
    <td>709</td>
    <td>1,194</td>
    <td>475</td>
    <td>766</td>
    <td>1,241</td>
    <td>455</td>
    <td>684</td>
    <td>1,139</td>
  </tr>
  <tr>
    <td>Total segment revenues</td>
    <td>1,931</td>
    <td>2,368</td>
    <td>4,300</td>
    <td>1,914</td>
    <td>2,416</td>
    <td>4,330</td>
    <td>1,818</td>
    <td>2,170</td>
    <td>3,988</td>
  </tr>
  <tr>
    <th colspan="10">Interventional</th>
  </tr>
  <tr>
    <td>Surgery (a)</td>
    <td>1,098</td>
    <td>299</td>
    <td>1,397</td>
    <td>946</td>
    <td>245</td>
    <td>1,192</td>
    <td>577</td>
    <td>89</td>
    <td>666</td>
  </tr>
  <tr>
    <td>Peripheral Intervention (a)</td>
    <td>787</td>
    <td>602</td>
    <td>1,389</td>
    <td>594</td>
    <td>451</td>
    <td>1,045</td>
    <td>14</td>
    <td>6</td>
    <td>19</td>
  </tr>
  <tr>
    <td>Urology and Critical Care</td>
    <td>797</td>
    <td>342</td>
    <td>1,140</td>
    <td>544</td>
    <td>256</td>
    <td>800</td>
    <td>—</td>
    <td>—</td>
    <td>—</td>
  </tr>
  <tr>
    <td>Total segment revenues</td>
    <td>2,682</td>
    <td>1,244</td>
    <td>3,926</td>
    <td>2,084</td>
    <td>953</td>
    <td>3,037</td>
    <td>591</td>
    <td>95</td>
    <td>685</td>
  </tr>
  <tr>
    <td>Total Company revenues</td>
    <td>9,730</td>
    <td>7,560</td>
    <td>17,290</td>
    <td>8,768</td>
    <td>7,215</td>
    <td>15,983</td>
    <td>6,504</td>
    <td>5,589</td>
    <td>12,093</td>
  </tr>
</table>

(a) Amounts presented in 2017 are associated with certain product offerings that were moved from the Medical segment to the Interventional segment in order to align with the reportable segment structure that became effective beginning in the second quarter of fiscal year 2018.